Imperative Care vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 53)
Imperative Care logo

Imperative Care

ChallengerHealthcare

Stroke & Vascular Thrombectomy Devices

Imperative Care is a commercial-stage MedTech company with FDA-cleared Zoom Stroke System used in 78,000+ procedures; raised $100M financing in March 2026 to expand its stroke thrombectomy portfolio and develop the Telos robotic stroke treatment.

AI VisibilityBeta
Overall Score
C53
Category Rank
#242 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
57
Perplexity
51
Gemini
56

About

Imperative Care is a commercial-stage medical technology company focused on advancing treatments for stroke and other thromboembolic diseases — conditions caused by blood clot formation in arteries and veins. Founded and headquartered in Campbell, California, Imperative Care designs and manufactures catheter-based devices for mechanical thrombectomy: the surgical removal of blood clots that cause strokes and other life-threatening vascular events. Its products are engineered to improve access to clots, aspiration performance, and overall procedure efficiency during time-critical stroke interventions.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

53
Overall Score
90
#242
Category Rank
#2
80
AI Consensus
83
stable
Trend
stable
57
ChatGPT
92
51
Perplexity
93
56
Gemini
89
53
Claude
96
49
Grok
95

Key Details

Category
Stroke & Vascular Thrombectomy Devices
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.